Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
SEC ownership of Wave Life Sciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001631574.
Disclosed value leader
GSK plc
Comparable rows
5/50
Latest evidence
05 Oct 2026
- Public ticker
- WVE on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
RA CAPITAL MANAGEMENT, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
5 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
RA CAPITAL MANAGEMENT, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
05 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001631574
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Wave Life Sciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
GSK plc
Comparable rows
5/50
Latest evidence
05 Oct 2026
3/4/5
13D/G
13F
Lead comparable stake: 17%
45 rows are not safely comparable across share classes.
13D/G row: RA CAPITAL MANAGEMENT, L.P.
Showing 1-8 of 50 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 17%.
5 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
17%
BlackRock, Inc.
6.1%
MAVERICK CAPITAL LTD
5.4%
FMR LLC
2.8%
Adage Capital Management, L.P.
0.53%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
13D/G
13F
Director, 10%+ Owner · Company
|
17%
Reported 13D/G
· 07 Aug 2026
|
$175,340,782
179,715 shares
mixed-class rows
|
+$54,631,065 | 05 Oct 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.1%
Reported 13D/G
· 31 Dec 2024
|
$111,566,297
19,202,461 shares
|
— | 30 Jun 2026 |
| MAVERICK CAPITAL LTD |
13F
13D/G
Company
|
5.4%
Reported 13D/G
· 31 Dec 2024
|
$59,715,848
10,278,115 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13D/G
13F
Company
|
2.8%
Reported 13D/G
· 31 Mar 2026
|
$37,284,027
5,192,761 shares
|
-$70,566,627 | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
0.53%
Reported 13D/G
· 31 Mar 2026
|
$7,180,000
1,000,000 shares
|
-$63,083,918 | 31 Mar 2026 |
| GSK plc |
3/4/5
13F
10%+ Owner · Company
|
—
denominator unverified
|
$346,668,129
18,245,691 shares
|
+$27,930,000 | 11 Dec 2025 |
| Peter Kolchinsky |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$175,340,782
103,515 shares
mixed-class rows
|
+$54,624,378 | 05 Oct 2026 |
| RA Capital Healthcare Fund LP |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$175,340,782
103,515 shares
mixed-class rows
|
+$54,624,378 | 05 Oct 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$230,252,592.
Buys
$246,434,199
Insiders: 5
Sells
$16,181,608
Insiders: 11
Net
+$230,252,592
Shares: +35,438,280
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 36,560,984
Shares: 1,122,704
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 23,996 | $0 | $135,072 | -$135,072 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 35,089,984 | 52,373 | $218,497,512 | $757,550 | +$217,739,962 |
| 9-12 | 1,471,000 | 1,046,335 | $27,936,688 | $15,288,985 | +$12,647,702 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Wave Life Sciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
GSK plc
Net 12M change
+$230,252,590
Latest report
05 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| GSK plc | 10%+ Owner | $346,668,129 | +$27,930,000 | +8.8% | Filing P/S | 11 Dec 2025 |
| RA Capital Healthcare Fund LP | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | Mixed | 05 Oct 2026 |
| Rajeev M. Shah | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | Mixed | 05 Oct 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10%+ Owner | $175,340,782 | +$54,631,065 | +45% | Mixed | 05 Oct 2026 |
| Peter Kolchinsky | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | Mixed | 05 Oct 2026 |
| Ken Takanashi | Director | $55,933,904 | -$23,223 | -0.04% | Mixed | 05 Oct 2026 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $5,490,908 | -$43,417 | -0.78% | Filing P/S | 05 Feb 2026 |
| Gregory L. Verdine | Director | $4,991,798 | -$269,461 | -5.1% | Mixed | 05 Oct 2026 |
| Paul Bolno | President and CEO, Director | $3,705,744 | -$140,956 | -3.7% | Filing P/S | 05 Feb 2026 |
| Kyle Moran | Chief Financial Officer | $1,807,478 | -$4,152,238 | -70% | Filing P/S | 05 Feb 2026 |
| Chris Francis | SVP, Corporate Development, Head of Emerging Areas | $928,005 | -$7,102,264 | -88% | Filing P/S | 26 Feb 2026 |
| Erik Ingelsson | Chief Scientific Officer | $637,022 | Mixed | 09 Apr 2026 | ||
| Mark Corrigan | Director | $405,282 | -$217,297 | -35% | Mixed | 05 Oct 2026 |
| Christopher I. Wright | Chief Medical Officer | $330,785 | Mixed | 09 Apr 2026 | ||
| Heidi L. Wagner | Director | $270,029 | -$231,070 | -46% | Mixed | 05 Oct 2026 |
| Henry Christian O | Director | $228,854 | -$1,369,324 | -86% | Mixed | 05 Oct 2026 |
| Aik Na Tan | Director | $150,057 | -$1,825,755 | -92% | Mixed | 05 Oct 2026 |
| Adrian Rawcliffe | Director | $0 | -$806,604 | -100% | Mixed | 05 Oct 2026 |
| Michael A. Panzara | Chief Medical Officer, Head of Therapeutics Discovery and Development | Mixed | 25 Jul 2022 |
Recent insider transactions for Wave Life Sciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | WVE | Common Stock | Award | 37.1% | 10,700 | 39,515 | 05 Oct 2026 | See footnotes | ||
| RA CAPITAL MANAGEMENT, L.P. | WVE | Common Stock | Award | 37.1% | 10,700 | 39,515 | 05 Oct 2026 | See footnotes | ||
| Ra Capital Management, L.P. | WVE | Common Stock | Award | 37.1% | 10,700 | 39,515 | 05 Oct 2026 | See footnotes | ||
| Ra Capital Management, L.P. | WVE | Common Stock | Award | 37.1% | 10,700 | 39,515 | 05 Oct 2026 | See footnotes | ||
| RA CAPITAL MANAGEMENT, L.P. | WVE | Stock Option (Right to Buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | See Footnotes | |||
| RA CAPITAL MANAGEMENT, L.P. | WVE | Stock Option (Right to Buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | WVE | Stock Option (Right to Buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | WVE | Stock Option (Right to Buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | See Footnotes | |||
| Gregory L. Verdine | WVE | Common Stock | Award | 5.63% | 10,700 | 200,917 | 05 Oct 2026 | Direct | ||
| Gregory L. Verdine | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Aik Na Tan | WVE | Common Stock | Award | 42.8% | 10,700 | 35,668 | 05 Oct 2026 | Direct | ||
| Aik Na Tan | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Ken Takanashi | WVE | Common Stock | Award | 53.3% | 10,700 | 30,779 | 05 Oct 2026 | Direct | ||
| Ken Takanashi | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Mark Corrigan | WVE | Common Stock | Award | 37.1% | 10,700 | 39,515 | 05 Oct 2026 | Direct | ||
| Mark Corrigan | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Adrian Rawcliffe | WVE | Common Stock | Award | 10,700 | 10,700 | 05 Oct 2026 | Direct | |||
| Adrian Rawcliffe | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Heidi L. Wagner | WVE | Common Stock | Award | 23.8% | 10,700 | 55,630 | 05 Oct 2026 | Direct | ||
| Heidi L. Wagner | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Henry Christian O | WVE | Common Stock | Award | 84.2% | 10,700 | 23,400 | 05 Oct 2026 | Direct | ||
| Henry Christian O | WVE | Stock Option (right to buy) | Award | 64,000 | 64,000 | 05 Oct 2026 | Direct | |||
| Adrian Rawcliffe | WVE | Common Stock | Sale | -100% | $67,183 | $5.29 | -12,700 | 0 | 12 Aug 2026 | Direct |
| Heidi L. Wagner | WVE | Common Stock | Sale | -13.5% | $42,070 | $6.01 | -7,000 | 44,930 | 11 Aug 2026 | Direct |
| Heidi L. Wagner | WVE | Common Stock | Options Exercise | 15.6% | 7,000 | 51,930 | 11 Aug 2026 | Direct | ||
| Heidi L. Wagner | WVE | Stock Option (right to buy) | Options Exercise | -100% | -7,000 | 0 | 11 Aug 2026 | Direct | ||
| Ken Takanashi | WVE | Common Stock | Sale | -16.1% | $23,223 | $6.01 | -3,864 | 20,079 | 11 Aug 2026 | Direct |
| Aik Na Tan | WVE | Common Stock | Sale | -1.7% | $2,596 | $6.01 | -432 | 24,968 | 11 Aug 2026 | Direct |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| Ken Takanashi | WVE | Ordinary Shares | Conversion of derivative security | 68.4% | 3,901,348 | 9,606,408 | 23 Mar 2026 | See Footnote | ||
| Ken Takanashi | WVE | Series A Preferred Shares | Conversion of derivative security | -100% | -3,901,348 | 0 | 23 Mar 2026 | See Footnote | ||
| Chris Francis | WVE | Ordinary Shares | Sale | -34.9% | $499,593 | $15.05 | -33,194 | 61,867 | 26 Feb 2026 | Direct |
| Chris Francis | WVE | Ordinary Shares | Options Exercise | 71.3% | 33,194 | 79,767 | 26 Feb 2026 | Direct | ||
| Chris Francis | WVE | Share Option (right to buy) | Options Exercise | -35.2% | -33,194 | 61,175 | 26 Feb 2026 | Direct | ||
| Kyle Moran | WVE | Ordinary Shares | Sale | -2.6% | $48,259 | $13.45 | -3,588 | 134,385 | 09 Feb 2026 | Direct |
| Paul Bolno | WVE | Ordinary Shares | Sale | -3.66% | $140,956 | $13.45 | -10,480 | 275,520 | 09 Feb 2026 | Direct |
| Chris Francis | WVE | Ordinary Shares | Sale | -2.95% | $25,326 | $13.45 | -1,883 | 61,867 | 09 Feb 2026 | Direct |
| Chandra Vargeese | WVE | Ordinary Shares | Sale | -0.78% | $43,417 | $13.45 | -3,228 | 408,246 | 09 Feb 2026 | Direct |
| Kyle Moran | WVE | Ordinary Shares | Award | 49.4% | 45,625 | 137,973 | 05 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.